IDVYNSO Drug Patent Profile

When do Idvynso patents expire, and what generic alternatives are available?

Idvynso is a drug marketed by MSD and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-six patent family members in forty-seven countries.

The generic ingredient in IDVYNSO is doravirine; islatravir. One supplier is listed for this compound. Additional details are available on the doravirine; islatravir profile page.

DrugPatentWatch^® Generic Entry Outlook for Idvynso

Idvynso will be eligible for patent challenges on April 20, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 20, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IDVYNSO

International Patents:	86
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IDVYNSO

IDVYNSO is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes			Y	Y
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes				Y
Msd	IDVYNSO	doravirine; islatravir	TABLET;ORAL	216964-001	Apr 20, 2026		RX	Yes	Yes

International Patents for IDVYNSO

See the table below for patents covering IDVYNSO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E388958
Canada	2502109	DERIVE DE 2-HALOADENOSINE AVEC SUBSTITUTION SUR LE CARBONE EN POSITION 4' (4'-C-SUBSTITUTED-2-HALOADENOSINE DERIVATIVE)
Germany	602005005240
European Patent Office	1589026	Dérivés de l'adénosine 2-halogénée et substituée en 4'-C (4'-C-Substituted-2-Haloadenosine derivative)
Spain	2300892

Supplementary Protection Certificates for IDVYNSO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2924034	PA2019507,C2924034	Lithuania		PRODUCT NAME: DORAVIRINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, DERINYJE SU LAMIVUDINU IR TENOFOVIRO DIZOPROKSILIO FUMARATU; REGISTRATION NO/DATE: EU/1/18/1333 20181122
2924034	LUC00114	Luxembourg		PRODUCT NAME: DORAVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC LA LAMIVUDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI EN COMBINAISON AVEC DU TENOFOVIR OU UN DE SES ESTERS, EN PARTICULIER UN ESTER DE DISOPROXIL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER UN SEL DE FUMARATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1333 20181126
2552902	201940022	Slovenia		PRODUCT NAME: DORAVIRIN OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/18/1332/001-002, EU/1/18/1333/001-002; DATE OF NATIONAL AUTHORISATION: 20181122; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2924034	CR 2019 00024	Denmark		PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND IN COMBINATION WITH TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126
2552902	24/2019	Austria		PRODUCT NAME: DORAVIRIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1333/001-002 (MITTEILUNG) 20181126